PDF, Patent Landscape Report on Atazanavir - WIPO

The three sections of Figure 22 follow the development of the combined Novartis and BMSportfolio on Atazanavir. The top section of the table shows that the portfolio includesgranted patents and also pending applications that were filed since 2002. The inventionsfound by chemical searching were filed beginning in 1995, but the clinically-orientedcollection begins in 1999, with the Atazanavir name per se appearing in 2001. From thebeginning, in 1995, utility for treatment of HIV was claimed, and Atazanavir was of course,not the first composition in this drug class, with multiple predecessors in the class, led byRoche’s Saquinavir that had was approved by the FDA in 1995, and which is now offpatent.The mid-section of the table reviews the different aspects of drug development mentionedin patents in the Novartis-BMS portfolio. Use of the drug in combination was included in thefounder patent, since much had already been learned about combination treatment of HIVby 1995. <strong>Patent</strong>ing of synthetic approaches persists over the entire time frame, andformulation patents are noted starting in 1998. Specific combinations begin to appear in1998, and combinations addressing both the same (PI) and different targets are mentioned,with the latest being viral fusion inhibitors.Figure 22. Timelines for Atazanavir Development CategoriesThe last section of the table deals with clinical indications other than HIV infection, andthese were not filed until after approval for the HIV indication was received.28